TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12791820

Group type: EXPERIMENTAL
Intervention: 99mTc-ciprofloxacin scintigraphy
Number of subjects: 27
Study: 10652395

Group type: EXPERIMENTAL
Intervention: Septoplasty surgery
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Nasal Health Survey
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: General health measures (Short Form-12)
Number of subjects: 161
Study: 8773887

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive Tissucol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional subciliary suturing (5-0 running suture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 40
Study: 1361310

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.0 micrograms/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 and 2.0 micrograms/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31671191

Group type: EXPERIMENTAL
Intervention: Olaparib and cediranib
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Olaparib and durvalumab
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Durvalumab and chemotherapy (high PD-L1 expression)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Durvalumab, tremelimumab, and chemotherapy (low PD-L1 expression)
Number of subjects: 68
Study: 28230798

Group type: EXPERIMENTAL
Intervention: Village-based nutrition intervention including nutritional education, written materials, and SMS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Village-based nutrition intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Folic acid education and SMS intervention
Number of subjects: 60
Study: 26923574

Group type: EXPERIMENTAL
Intervention: Trans-Sylvian (TS) approach
Number of subjects: 18

Group type: COMPARATOR
Intervention: Trans-Cortical (TC) approach
Number of subjects: 18
Study: 23037612

Group type: EXPERIMENTAL
Intervention: Treadmill running (TR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stationary running (SR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Jumping jack (JJ)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Forward kick (FK)
Number of subjects: 9

Group type: COMPARATOR
Intervention: %V[Combining Dot Above]O2max
Number of subjects: 9

Group type: COMPARATOR
Intervention: RPE
Number of subjects: 9
Study: 21235330

Group type: EXPERIMENTAL
Intervention: Paper strips
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paper points
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Washing the periodontal pocket
Number of subjects: 36
Study: 19207276

Group type: EXPERIMENTAL
Intervention: Testosterone and vardenafil
Number of subjects: 28
Study: 17370714

Group type: EXPERIMENTAL
Intervention: Dietary restriction and physical activity with behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-obesity drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment programmes
Number of subjects: 0
Study: 15366318

Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 0
Study: 11120972

Group type: EXPERIMENTAL
Intervention: Concentration-controlled therapy (11 subjects)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy (13 subjects)
Number of subjects: 24
Study: 9711340

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 7975357

Group type: EXPERIMENTAL
Intervention: Enalapril (ENAP KRKA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (Vasocardin Slovakofarma)
Number of subjects: 20
Study: 2737801

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate hydrochloride
Number of subjects: 9
Study: 31181144

Group type: EXPERIMENTAL
Intervention: EHR-based health information technology intervention
Number of subjects: 0
Study: 28399980

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 841
Study: 26493461

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme delivered through a tablet computer, 2 hours of exercises per week for 2 years.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Education programme focused on health-related information relevant to older adults, delivered through the tablet computer via weekly fact sheets.
Number of subjects: 500
Study: 24034466

Group type: EXPERIMENTAL
Intervention: E2 V/DNG
Number of subjects: 213

Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: E2 V/DNG and EE/LNG
Number of subjects: 213
Study: 19836218

Group type: EXPERIMENTAL
Intervention: Low GI and Low GL breakfast (LGI-LGL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High GI and High GL breakfast (HGI-HGL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High GI and Low GL breakfast (HGI-LGL)
Number of subjects: 16
Study: 18643839

Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy (insulin detemir once daily and insulin aspart mealtimes)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (30% rapid-acting insulin aspart), twice daily
Number of subjects: 719
Study: 17848650

Group type: EXPERIMENTAL
Intervention: High doses of folic acid (40 mg), pyridoxine hydrochloride (100 mg), and cyanocobalamin (2 mg) daily
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: High doses of folic acid and B vitamins
Number of subjects: 2056
Study: 15054373

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 microg/day after saline lavage
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 600 microg/day after saline lavage
Number of subjects: 162

Group type: COMPARATOR
Intervention: Saline lavage only (Control group)
Number of subjects: 162
Study: 11331147

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9141924

Group type: EXPERIMENTAL
Intervention: Alfentanil (40 micrograms/kg IV bolus) followed by infusion (1 microgram.kg‐1.min‐1 during surgery and 0.5 microgram.kg‐1.min‐1 postoperatively)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sufentanil (5 micrograms/kg IV bolus) followed by infusion (0.01 microgram.kg‐1.min‐1 during surgery and 0.005 microgram.kg‐1.min‐1 postoperatively)
Number of subjects: 14
Study: 9355669

Group type: EXPERIMENTAL
Intervention: Prednisone (more than 0.16 mg/kg/day for more than 6 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 14
Study: 2852609

Group type: EXPERIMENTAL
Intervention: Fluconazole, single oral 150 mg dose
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ketoconazole, 200 mg twice daily for 5 days
Number of subjects: 183
Study: 30445389

Group type: EXPERIMENTAL
Intervention: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist/Treatment-as-Usual (WL/TAU)
Number of subjects: 128
Study: 28785847

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) + Albendazole (ABZ)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 155
Study: 25761542

Group type: EXPERIMENTAL
Intervention: Serum methylglyoxal
Number of subjects: 882
Study: 23963046

Group type: EXPERIMENTAL
Intervention: Sildenafil (doses: 37.5 mg, 50 mg, 100 mg)
Number of subjects: 26
Study: 21873906

Group type: EXPERIMENTAL
Intervention: Assisted Sprint Training (AST)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training (RST)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional Sprint Training (TST)
Number of subjects: 27
Study: 19289615

Group type: EXPERIMENTAL
Intervention: p16(INK4A) positive tumors
Number of subjects: 156
Study: 17210079

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 60
Study: 15785088

Group type: EXPERIMENTAL
Intervention: Acyclic retinoid (oral administration for 12 months)
Number of subjects: 0
Study: 12034658

Group type: EXPERIMENTAL
Intervention: Losartan treatment for 12 months in patients with severe fibrosis (n=7)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (nonsevere fibrosis, n=12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All hypertensives
Number of subjects: 34
Study: 10716202

Group type: EXPERIMENTAL
Intervention: Normal sleep
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 13
Study: 7790707

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (300 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2220013

Group type: EXPERIMENTAL
Intervention: 5 mg pimobendan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg pimobendan
Number of subjects: 12
Study: 87829

Group type: EXPERIMENTAL
Intervention: 2-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: 3-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Standard 12-month control regimen
Number of subjects: 1072
Study: 31796570

Group type: EXPERIMENTAL
Intervention: Nonalbuminuric CKD
Number of subjects: 10185

Group type: EXPERIMENTAL
Intervention: Albuminuric CKD
Number of subjects: 10185

Group type: EXPERIMENTAL
Intervention: Albuminuric non-CKD
Number of subjects: 10185

Group type: COMPARATOR
Intervention: No CKD
Number of subjects: 10185
Study: 31124975

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum and steep Trendelenburg position
Number of subjects: 90
Study: 28473058

Group type: EXPERIMENTAL
Intervention: Grape powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25938681

Group type: EXPERIMENTAL
Intervention: Peer counselled promotion of exclusive breastfeeding (EBF) for 6 months
Number of subjects: 765

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 765
Study: 24284610

Group type: EXPERIMENTAL
Intervention: Chewable tablet (200 mg vitamin C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Kiwifruit-derived vitamin C (equivalent dose from gold kiwifruit)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Kiwifruit-derived vitamin C
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vitamin C tablet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 9
Study: 22152107

Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 143
Study: 19418107

Group type: COMPARATOR
Intervention: Generic print pamphlet
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Tailored print pamphlet
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Tailored print pamphlet and tailored counseling call
Number of subjects: 412
Study: 16960663

Group type: EXPERIMENTAL
Intervention: Antireflux stent
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 15496648

Group type: EXPERIMENTAL
Intervention: Amprenavir-containing combination therapy with nucleoside reverse transcriptase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C(min)/IC(50) ratio
Number of subjects: 0
Study: 11783936

Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 34

Group type: COMPARATOR
Intervention: NFkappaB oligonucleotide decoy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sodium salicylate
Number of subjects: 34
Study: 9151545

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8421205

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50, 75, or 100 micrograms)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 93
Study: 3501546

Group type: EXPERIMENTAL
Intervention: Oral leucovorin calcium (5-formyl-THF) at doses of 40 mg, 60 mg, 80 mg, and 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg oral leucovorin calcium
Number of subjects: 30

Group type: COMPARATOR
Intervention: 200 mg intravenous leucovorin calcium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral leucovorin calcium
Number of subjects: 30
Study: 31537115

Group type: EXPERIMENTAL
Intervention: Mini-percutaneous nephrolithotomy (mPNL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (sPNL)
Number of subjects: 148
Study: 29215299

Group type: EXPERIMENTAL
Intervention: CSII therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: MDI therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CSII therapy at 12 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CSII therapy after crossover from MDI
Number of subjects: 23
Study: 27780350

Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 58

Group type: COMPARATOR
Intervention: Email
Number of subjects: 58
Study: 24766974

Group type: EXPERIMENTAL
Intervention: Amiodarone (up to 450 mg)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Lidocaine (up to 180 mg)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3000
Study: 24135924

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study: 21569282

Group type: EXPERIMENTAL
Intervention: WHS mental module with screening and feedback, plus consultation with an occupational physician for impairments in mental health or work functioning.
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: WHS mental module with tailored self-help e-mental health interventions based on individual mental health state and work functioning.
Number of subjects: 1731

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Both intervention arms.
Number of subjects: 1731
Study: 18177789

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Individually randomized trials
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials (adjusted for clustering)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Baseline imbalances in cluster randomized studies
Number of subjects: 34

Group type: COMPARATOR
Intervention: Baseline imbalances in individually randomized studies
Number of subjects: 34
Study: 17135806

Group type: EXPERIMENTAL
Intervention: Self-rated CGIC
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Study partner-rated CGIC
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Comparison of subject ratings with partner ratings
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Overall change over 3 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Home-based vs clinic-based ratings
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Correlations with change scores of selected clinical rating scales
Number of subjects: 650
Study: 12548295

Group type: EXPERIMENTAL
Intervention: 100 g/day of berries (black currants, lingonberries and bilberries) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Habitual Finnish diets (control group)
Number of subjects: 40
Study: 10702460

Group type: EXPERIMENTAL
Intervention: 0.2 microg. kg(‐1). h(‐1) dexmedetomidine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.6 microg. kg(‐1). h(‐1) dexmedetomidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study: 9196412

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 22

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 22
Study: 8403586

Group type: EXPERIMENTAL
Intervention: Sustained-release flurbiprofen 200 mg
Number of subjects: 24
Study: 2906886

Group type: EXPERIMENTAL
Intervention: 4 mg acrivastine given three times daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine given three times daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 1 mg clemastine given three times daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31425456

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise (HI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-Volume Resistance Exercise (HV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 30040140

Group type: COMPARATOR
Intervention: Low-intensity Fracture Liaison Service (active-control)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: High-intensity Fracture Liaison Service (case manager)
Number of subjects: 361
Study: 27029362

Group type: EXPERIMENTAL
Intervention: Cadmium exposure group
Number of subjects: 298
Study: 25322607

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low maintain dose (0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high maintain dose (0.7 microg x kg(‐1) x h(‐1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 120
Study: 23692634

Group type: EXPERIMENTAL
Intervention: Tailored strategy to support full clinical pathway implementation for asthma.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tailored strategy to support full clinical pathway implementation for gastroenteritis.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group for asthma pathway implementation.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group for gastroenteritis pathway implementation.
Number of subjects: 16
Study: 20484548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3264

Group type: COMPARATOR
Intervention: Zinc (10 mg)
Number of subjects: 3264

Group type: COMPARATOR
Intervention: Iron + Folic Acid (12.5 mg iron + 50 microg folic acid)
Number of subjects: 3264

Group type: COMPARATOR
Intervention: Zinc + Iron + Folic Acid (10 mg zinc + 12.5 mg iron + 50 microg folic acid)
Number of subjects: 3264
Study: 17593932

Group type: EXPERIMENTAL
Intervention: Sea buckthorn berries
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 16720676

Group type: EXPERIMENTAL
Intervention: SNAP II™ index
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BIS XP™ index
Number of subjects: 42
Study: 14572943

Group type: EXPERIMENTAL
Intervention: Video presentations about nicotine replacement treatment (NRT)
Number of subjects: 504
Study: 10470219

Group type: EXPERIMENTAL
Intervention: Inhaled IL-2 (high-dose)
Number of subjects: 116
Study: 7567847

Group type: EXPERIMENTAL
Intervention: Three million units of alpha‐lymphoblastoid interferon (n = 30)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Six million units of alpha‐lymphoblastoid interferon (n = 30)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No treatment (Control group, n = 25)
Number of subjects: 85
Study: 1770153

Group type: EXPERIMENTAL
Intervention: 1.0 mg of alprazolam
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 7015093

Group type: EXPERIMENTAL
Intervention: Synthetic secretin (Hoe 069 + depot component)
Number of subjects: 100
Study: 28513897

Group type: EXPERIMENTAL
Intervention: Direct light-activated composite resin restorations
Number of subjects: 138
Study: 28674922

Group type: EXPERIMENTAL
Intervention: Voluntary contractions (VOL group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Electro-induced contractions (NMES group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study: 25848210

Group type: COMPARATOR
Intervention: HX‐1171, single ascending doses of 20, 40, 80, 160, 300, 600, 1,200, 1,500 or 2,000 mg administered to 67 subjects.
Number of subjects: 83

Group type: COMPARATOR
Intervention: HX‐1171, multiple ascending doses of 500 or 1,000 mg administered to 16 subjects for 14 days.
Number of subjects: 83

Group type: COMPARATOR
Intervention: HX‐1171, single and multiple doses.
Number of subjects: 83
Study: 24384083

Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (no NR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (mild NR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (maximum NR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 21
Study: 21084767

Group type: EXPERIMENTAL
Intervention: Ammonium chloride treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium bicarbonate treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ammonium chloride treatment (PEPT2*2/*2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium bicarbonate treatment (PEPT2*1/*1)
Number of subjects: 16
Study: 19861194

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (IT group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral prednisolone (oral group)
Number of subjects: 63
Study: 17978987

Group type: EXPERIMENTAL
Intervention: Combination of denicotinized cigarettes (Quest 3) and 21‐mg nicotine patch for 2 weeks before the quit date
Number of subjects: 98

Group type: COMPARATOR
Intervention: Light cigarettes (Quest 1) during the 2 weeks before the quit date
Number of subjects: 98
Study: 15195985

Group type: EXPERIMENTAL
Intervention: Home training (HT) - twice‐daily functional balance and strength exercises and 3 group meetings
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combined training (CT) - group training twice weekly and the same home exercises
Number of subjects: 77

Group type: COMPARATOR
Intervention: Home training (HT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Combined training (CT)
Number of subjects: 77
Study: 11706532

Group type: EXPERIMENTAL
Intervention: CR10 Borg's scale
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VAS (visual analogue scale)
Number of subjects: 15